SCHEMBL17520338

SCHEMBL17520338

COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 18/20 1.00
KDR P35968 4/20 0.86
EPHB4 P54760 3/20 0.86
FLT4 P35916 2/20 0.86
CIT O14578 1/20 0.86
GAK O14976 1/20 0.86
EPHB6 O15197 1/20 0.86
ABCC4 O15439 1/20 0.86
DAPK3 O43293 1/20 0.86
RIPK2 O43353 1/20 0.86
NR1I2 O75469 1/20 0.86
RPS6KA4 O75676 1/20 0.86
STK17B O94768 1/20 0.86
STK10 O94804 1/20 0.86
PRKD3 O94806 1/20 0.86
ABCB11 O95342 1/20 0.86
MAP4K4 O95819 1/20 0.86
CHEK2 O96017 1/20 0.86
ABL1 P00519 1/20 0.86
ERBB2 P04626 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12012 1.00 EGFR (1.00) EGFRKDREPHB4FLT4CIT
SCHEMBL11395 0.99 EGFR (1.00) EGFRKDREPHB4FLT4CIT
SCHEMBL17520333 0.97 EGFR (0.95) EGFRKDREPHB4FLT4CIT
SCHEMBL11132 0.96 EGFR (1.00) EGFRKDREPHB4FLT4CIT
SCHEMBL17520332 0.96 EGFR (1.00) EGFRKDREPHB4FLT4CIT
SCHEMBL8669 0.95 EGFR (1.00) EGFRKDREPHB4FLT4CIT
SCHEMBL22338480 0.94 EGFR (0.92) EGFRKDREPHB4FLT4CIT
SCHEMBL18442386 0.93 EGFR (0.94) EGFRKDREPHB4FLT4CIT
SCHEMBL22336591 0.92 EGFR (0.86) EGFRKDREPHB4FLT4CIT
SCHEMBL4222431 0.92 EGFR (0.98) EGFRKDREPHB4FLT4CIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885EPHB4 4477/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885EPHB4 4477/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885EPHB4 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.